Oruka Interest Expense from 2010 to 2026

ORKA Stock   26.40  1.41  5.07%   
Oruka Therapeutics' Interest Expense is increasing over the years with slightly volatile fluctuation. Overall, Interest Expense is expected to go to about 1.4 M this year. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
First Reported
2010-12-31
Previous Quarter
1.3 M
Current Value
1.4 M
Quarterly Volatility
699.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oruka Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oruka Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.1 K, Interest Expense of 1.4 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 2.28, Dividend Yield of 0.8 or PTB Ratio of 0.73. Oruka financial statements analysis is a perfect complement when working with Oruka Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Oruka Stock
Check out the analysis of Oruka Therapeutics Correlation against competitors.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.

Latest Oruka Therapeutics' Interest Expense Growth Pattern

Below is the plot of the Interest Expense of Oruka Therapeutics over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Oruka Therapeutics' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oruka Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Expense10 Years Trend
Slightly volatile
   Interest Expense   
       Timeline  

Oruka Interest Expense Regression Statistics

Arithmetic Mean567,674
Geometric Mean57,996
Coefficient Of Variation123.16
Mean Deviation660,087
Median7,000
Standard Deviation699,121
Sample Variance488.8B
Range1.5M
R-Value0.68
Mean Square Error277.8B
R-Squared0.47
Significance0
Slope94,621
Total Sum of Squares7.8T

Oruka Interest Expense History

20261.4 M
20251.3 M
20211.5 M
2020 9000.0
2013 7000.0
2012 3000.0
2011 5000.0

About Oruka Therapeutics Financial Statements

Oruka Therapeutics stakeholders use historical fundamental indicators, such as Oruka Therapeutics' Interest Expense, to determine how well the company is positioned to perform in the future. Although Oruka Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oruka Therapeutics' assets and liabilities are reflected in the revenues and expenses on Oruka Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oruka Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest Expense1.3 M1.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Oruka Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oruka Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oruka Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oruka Therapeutics Stock:
Check out the analysis of Oruka Therapeutics Correlation against competitors.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oruka Therapeutics. If investors know Oruka will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oruka Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oruka Therapeutics is measured differently than its book value, which is the value of Oruka that is recorded on the company's balance sheet. Investors also form their own opinion of Oruka Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oruka Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oruka Therapeutics' market value can be influenced by many factors that don't directly affect Oruka Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oruka Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oruka Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oruka Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.